

Resource Summary Report

Generated by [nidm-terms](#) on Aug 9, 2026

pRL-TK 4x wt

RRID:Addgene_11313

Type: Plasmid

Proper Citation

RRID:Addgene_11313

Plasmid Information

URL: <http://www.addgene.org/11313>

Proper Citation: RRID:Addgene_11313

Insert Name: 4 bulged binding sites for CXCR4 siRNA antisense

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:15014042](#)

Vector Backbone Description: Backbone Marker:Promega; Backbone Size:4045; Vector Backbone:pRL-TK; Vector Types:Luciferase; Bacterial Resistance:Ampicillin

Comments: Two original binding sites, separated by 4 nt, were flanked by two of the original bulged binding sites, each 11 nt away. Flanking CXCR4 sites, with XhoI and SpeI restriction sites between them, were inserted into the XbaI site in the 3' UTR of the pRL-TK plasmid. The inner binding sites were then inserted by ligating annealed oligos into the XhoI and SpeI sites. See Addgene plasmid 11307 for cloning of binding sites into the backbone, used in Doench, Sharp 2003 paper.

Plasmid Name: pRL-TK 4x wt

Record Creation Time: 20220422T221552+0000

Record Last Update: 20260808T080456+0000

Ratings and Alerts

No rating or validation information has been found for pRL-TK 4x wt.

No alerts have been found for pRL-TK 4x wt.

Data and Source Information

Usage and Citation Metrics

We found 16 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Lörentz S, et al. (2026) SNAT1 (SLC38A1) Is Not the Main Glutamine Transporter in Melanoma, but Controls Metabolism via Glutamine-Dependent Activation of P62 (SQSTM1)/cMYC-Axis. *Cancers*, 18(7).

Liu Y, et al. (2026) CRTAC1 inhibits progression of lung adenocarcinoma by suppressing integrin/FAK signaling. *Oncogene*, 45(10), 946.

Xu J, et al. (2026) The Interaction of CircESR1 and HNRNPAB Regulates Cell Cycle Transition of Breast Cancer Cell. *International journal of biological sciences*, 22(3), 1520.

Ding Z, et al. (2026) TRAPPC4 Promotes GPX4 Stability to Drive Ferroptosis Resistance and Tumor Progression in Head and Neck Squamous Cell Carcinoma. *Cancer research*, 86(14), 3436.

Liu J, et al. (2026) ERK1/2 hijack STAT3 via Thr714 phosphorylation to suppress gene expression. *Cell communication and signaling : CCS*, 24(1).

Zuo X, et al. (2024) TNFRSF19 within the 13q12.12 Risk Locus Functions as a Lung Cancer Suppressor by Binding Wnt3a to Inhibit Wnt/ β -Catenin Signaling. *Molecular cancer research : MCR*, 22(3), 227.

Dai X, et al. (2024) Dihydroartemisinin inhibits the development of colorectal cancer by GSK-3 β /TCF7/MMP9 pathway and synergies with capecitabine. *Cancer letters*, 582, 216596.

Jing N, et al. (2024) PAX6 promotes neuroendocrine phenotypes of prostate cancer via enhancing MET/STAT5A-mediated chromatin accessibility. *Journal of experimental & clinical cancer research : CR*, 43(1), 144.

Chen D, et al. (2024) RUVBL1/2 Blockade Targets YTHDF1 Activity to Suppress m6A-Dependent Oncogenic Translation and Colorectal Tumorigenesis. *Cancer research*, 84(17), 2856.

Liao X, et al. (2023) Downregulation of BASP1 promotes temozolomide resistance in gliomas via epigenetic activation of the FBXO32/NF- κ B/MGMT axis. *Molecular cancer research : MCR*.

Miller AL, et al. (2023) DAB2IP Is a Bifunctional Tumor Suppressor That Regulates Wild-Type RAS and Inflammatory Cascades in KRAS Mutant Colon Cancer. *Cancer research*, 83(11), 1800.

Lin S, et al. (2023) Acquired resistance to EGFR-TKIs in NSCLC mediates epigenetic downregulation of MUC17 by facilitating NF- κ B activity via UHRF1/DNMT1 complex.

International journal of biological sciences, 19(3), 832.

Lin S, et al. (2023) UHRF1/DNMT1-MZF1 axis-modulated intragenic site-specific CpGI methylation confers divergent expression and opposing functions of PRSS3 isoforms in lung cancer. *Acta pharmaceutica Sinica. B*, 13(5), 2086.

Jin Z, et al. (2023) CRTAC1 enhances the chemosensitivity of non-small cell lung cancer to cisplatin by eliciting RyR-mediated calcium release and inhibiting Akt1 expression. *Cell death & disease*, 14(8), 563.

Yao C, et al. (2021) SIPA1 Enhances Aerobic Glycolysis Through HIF-2? Pathway to Promote Breast Cancer Metastasis. *Frontiers in cell and developmental biology*, 9, 779169.

Mudianto T, et al. (2021) Yap1 Mediates Trametinib Resistance in Head and Neck Squamous Cell Carcinomas. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 27(8), 2326.